Area of research
Hematology · Immunology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Immunodeficiency and Autoimmune Disorders, Acute Lymphoblastic Leukemia research, and Hemoglobinopathies and Related Disorders.
Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease.
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC.
Neurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined immunodeficiency (SCID): A PIDTC study.
Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging
Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel.
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121
Durable Clinical Benefits in Transfusion-Dependent Β-Thalassemia with Exagamglogene Autotemcel
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part III. Long-Term Impact of Chronic Graft-versus-Host Disease on Endocrinologic, Cardiovascular, and Metabolic Outcomes in Survivors of Pediatric Hematopoietic Cell Transplantation.
Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC
Durable Clinical Benefits in Severe Sickle Cell Disease with Exagamglogene Autotemcel
A Patient With NEMO Deficiency, Disseminated M. szulgai, and Post-HSCT Inflammatory Disease.
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines.
Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia.
Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
Busulfan and subsequent malignancy: An evidence-based risk assessment.
Elimination of Vaso-Occlusive Crises after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease
Begelomab Salvages Steroid Resistant Acute Graft Versus (SR aGVHD) Host Disease in Pediatric Patients: A Single Center Case Serie
Transfusion Independence after Exagamglogene Autotemcel in Patients with Transfusion-Dependent β-Thalassemia
Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Transfusion-Dependent Beta-Thalassemia